Korro Bio, Inc. (KRRO): restructuring charge — Korro Bio Q3 net loss $18.1M; cuts workforce 34%; Novo collaboration paused; KRRO-110 misses functional protein target

Korro Bio, Inc.

Cash, equivalents and securities $102.5M at Sept 30, 2025; net loss $18.1M for Q3.
Workforce reduction of ~34%; expects one-time restructuring charges of ~$2.4M in Q4 2025.
KRRO-110 produced functional M-AAT protein but peak total AAT ~10 µM missed protective 11 µM threshold; pivoting to GalNAc construct for AATD.
Nominated KRRO-121 for hyperammonemia; first-in-human filing anticipated H2 2026.
Novo Nordisk collaboration paused for 12 months; CMO Dr. Olugemo resigned effective Nov 12.

item 1.01 item 2.02 item 2.05 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 1.0

Korro Bio, Inc. announced a restructuring with charges of approximately $2.4 million (approximately 34%).

Type: restructuring
Charge: approximately $2.4 million
Headcount: approximately 34%

Exact text from the filing

On November 12, 2025, Korro implemented a strategic restructuring to extend cash runway, including a workforce reduction of approximately 34%. Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended December 31, 2025.

View on SEC.gov

Browse all restructurings & charges →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-277556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.